Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension).

Beghetti M, Schulze-Neick I, Berger RM, Ivy DD, Bonnet D, Weintraub RG, Saji T, Yung D, Mallory GB, Geiger R, Berger JT, Barst RJ, Humpl T; TOPP Investigators.

Int J Cardiol. 2016 Jan 15;203:325-30. doi: 10.1016/j.ijcard.2015.10.087. Epub 2015 Oct 23.

PMID:
26583838
2.

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.

Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thébaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society.

Circulation. 2015 Nov 24;132(21):2037-99. doi: 10.1161/CIR.0000000000000329. Epub 2015 Nov 3. Erratum in: Circulation. 2016 Jan 26;133(4):e368.

PMID:
26534956
3.

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.

Frost AE, Barst RJ, Hoeper MM, Chang HJ, Frantz RP, Fukumoto Y, Galié N, Hassoun PM, Klose H, Matsubara H, Morrell NW, Peacock AJ, Pfeifer M, Simonneau G, Tapson VF, Torres F, Dario Vizza C, Lawrence D, Yang W, Felser JM, Quinn DA, Ghofrani HA.

J Heart Lung Transplant. 2015 Nov;34(11):1366-75. doi: 10.1016/j.healun.2015.05.025. Epub 2015 Jun 11.

4.

Validation of two predictive models for survival in pulmonary arterial hypertension.

Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemarié JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD.

Eur Respir J. 2015 Jul;46(1):152-64. doi: 10.1183/09031936.00004414. Epub 2015 Apr 2.

5.

[Pediatric pulmonary hypertension].

Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, Haworth SG, Raj JU, Rosenzweig EB, Neick IS, Steinhorn RH, Beghetti M.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:153-64. Turkish.

6.

[New trial designs and potential therapies for pulmonary artery hypertension].

Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:106-18. Turkish.

7.

Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study.

Frantz RP, Schilz RJ, Chakinala MM, Badesch DB, Frost AE, McLaughlin VV, Barst RJ, Rosenberg DM, Miller DP, Hartline BK, Benton WW, Farber HW.

Chest. 2015 Feb;147(2):484-494. doi: 10.1378/chest.14-1004.

8.

Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI).

Lopes AA, Barst RJ, Haworth SG, Rabinovitch M, Al Dabbagh M, Del Cerro MJ, Ivy D, Kashour T, Kumar K, Harikrishnan S, D'Alto M, Thomaz AM, Zorzanelli L, Aiello VD, Mocumbi AO, Santana MV, Galal AN, Banjar H, Tamimi O, Heath A, Flores PC, Diaz G, Sandoval J, Kothari S, Moledina S, Gonçalves RC, Barreto AC, Binotto MA, Maia M, Al Habshan F, Adatia I.

Pulm Circ. 2014 Jun;4(2):330-41. doi: 10.1086/675995. Erratum in: Pulm Circ. 2014 Sep;4(3):531.

9.

Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom.

Gladwin MT, Barst RJ, Gibbs JS, Hildesheim M, Sachdev V, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Berman Rosenzweig E, Badesch DB, Lanzkron S, Castro OL, Taylor JG 6th, Goldsmith JC, Kato GJ, Gordeuk VR, Machado RF; walk-PHaSST Investigators and Patients.

PLoS One. 2014 Jul 2;9(7):e99489. doi: 10.1371/journal.pone.0099489. eCollection 2014.

10.

Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB; PACES Study Group.

J Heart Lung Transplant. 2014 Jul;33(7):689-97. doi: 10.1016/j.healun.2014.02.019. Epub 2014 Feb 22.

PMID:
24815795
11.

STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.

Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD; STARTS-2 Investigators.

Circulation. 2014 May 13;129(19):1914-23. doi: 10.1161/CIRCULATIONAHA.113.005698. Epub 2014 Mar 17.

PMID:
24637559
12.

An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, Kato GJ, Ataga KI, Gibbs JS, Castro O, Rosenzweig EB, Sood N, Hsu L, Wilson KC, Telen MJ, Decastro LM, Krishnamurti L, Steinberg MH, Badesch DB, Gladwin MT; American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease.

Am J Respir Crit Care Med. 2014 Mar 15;189(6):727-40. doi: 10.1164/rccm.201401-0065ST.

13.

Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.

Shah AM, Campbell P, Rocha GQ, Peacock A, Barst RJ, Quinn D, Solomon SD; IMPRES Investigators.

Eur Heart J. 2015 Mar 7;36(10):623-32. doi: 10.1093/eurheartj/ehu035. Epub 2014 Feb 23.

14.

New trial designs and potential therapies for pulmonary artery hypertension.

Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D82-91. doi: 10.1016/j.jacc.2013.10.026. Review.

15.

Pediatric pulmonary hypertension.

Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, Fleming TR, Haworth SG, Raj JU, Rosenzweig EB, Schulze Neick I, Steinhorn RH, Beghetti M.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D117-26. doi: 10.1016/j.jacc.2013.10.028. Review.

16.

Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association.

Giglia TM, Massicotte MP, Tweddell JS, Barst RJ, Bauman M, Erickson CC, Feltes TF, Foster E, Hinoki K, Ichord RN, Kreutzer J, McCrindle BW, Newburger JW, Tabbutt S, Todd JL, Webb CL; American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Stroke Council.

Circulation. 2013 Dec 17;128(24):2622-703. doi: 10.1161/01.cir.0000436140.77832.7a. Epub 2013 Nov 13. No abstract available. Erratum in: Circulation. 2014 Jan 14;129(2):e23.

PMID:
24226806
17.

Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).

Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB.

Am J Cardiol. 2014 Jan 1;113(1):147-55. doi: 10.1016/j.amjcard.2013.09.032. Epub 2013 Oct 4.

PMID:
24176071
18.

One-year experience with intravenous treprostinil for pulmonary arterial hypertension.

Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV.

J Heart Lung Transplant. 2013 Sep;32(9):889-96. doi: 10.1016/j.healun.2013.06.008.

PMID:
23953817
19.

Clinical trials in neonates and children: Report of the pulmonary hypertension academic research consortium pediatric advisory committee.

Adatia I, Haworth SG, Wegner M, Barst RJ, Ivy D, Stenmark KR, Karkowsky A, Rosenzweig E, Aguilar C.

Pulm Circ. 2013 Jan;3(1):252-66. doi: 10.4103/2045-8932.109931.

20.

Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice.

Beghetti M, Berger RM, Schulze-Neick I, Day RW, Pulido T, Feinstein J, Barst RJ, Humpl T; TOPP Registry Investigators.

Eur Respir J. 2013 Sep;42(3):689-700. doi: 10.1183/09031936.00140112. Epub 2013 Apr 5.

21.

Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension.

Germain M, Eyries M, Montani D, Poirier O, Girerd B, Dorfmüller P, Coulet F, Nadaud S, Maugenre S, Guignabert C, Carpentier W, Vonk-Noordegraaf A, Lévy M, Chaouat A, Lambert JC, Bertrand M, Dupuy AM, Letenneur L, Lathrop M, Amouyel P, de Ravel TJ, Delcroix M, Austin ED, Robbins IM, Hemnes AR, Loyd JE, Berman-Rosenzweig E, Barst RJ, Chung WK, Simonneau G, Trégouët DA, Humbert M, Soubrier F.

Nat Genet. 2013 May;45(5):518-21. doi: 10.1038/ng.2581. Epub 2013 Mar 17.

22.

Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.

Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD.

Chest. 2013 Jul;144(1):160-168. doi: 10.1378/chest.12-2417.

PMID:
23429998
23.

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, Gómez-Sánchez MA, Grimminger F, Grünig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA.

Circulation. 2013 Mar 12;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12.

PMID:
23403476
24.

Congenital heart disease and pulmonary hypertension: pharmacology and feasibility of late surgery.

Rosenzweig EB, Barst RJ.

Prog Cardiovasc Dis. 2012 Sep-Oct;55(2):128-33. doi: 10.1016/j.pcad.2012.07.004. Review.

PMID:
23009909
25.

The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe.

Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst RJ, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Goldsmith JC, Gordeuk VR, Gladwin MT; Walk-PHASST Investigators and Patients.

Haematologica. 2013 Mar;98(3):464-72. doi: 10.3324/haematol.2012.068965. Epub 2012 Sep 14.

26.

Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.

Kitterman N, Poms A, Miller DP, Lombardi S, Farber HW, Barst RJ.

Mayo Clin Proc. 2012 Sep;87(9):825-34. doi: 10.1016/j.mayocp.2012.05.014. Epub 2012 Aug 9.

27.

Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension.

Barst RJ, Channick R, Ivy D, Goldstein B.

Pulm Circ. 2012 Apr-Jun;2(2):139-47. doi: 10.4103/2045-8932.97589. Erratum in: Pulm Circ. 2012 Jul-Sep;2(3):iv.

28.

Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.

Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, Chan M, Beardsworth A, Barst RJ; PHIRST Study Group.

J Am Coll Cardiol. 2012 Aug 21;60(8):768-74. doi: 10.1016/j.jacc.2012.05.004. Epub 2012 Jul 18.

29.

Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry.

Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD.

Chest. 2013 Jan;143(1):185-195. doi: 10.1378/chest.11-1387.

PMID:
22661451
30.

An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD.

Chest. 2012 Aug;142(2):448-456. doi: 10.1378/chest.11-1460.

PMID:
22281797
31.

Clinical features of paediatric pulmonary hypertension: a registry study.

Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ.

Lancet. 2012 Feb 11;379(9815):537-46. doi: 10.1016/S0140-6736(11)61621-8. Epub 2012 Jan 11.

32.

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL.

Circulation. 2012 Jan 17;125(2):324-34. doi: 10.1161/CIRCULATIONAHA.110.016667. Epub 2011 Nov 29.

PMID:
22128226
33.

Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.

Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD.

Circulation. 2012 Jan 3;125(1):113-22. doi: 10.1161/CIRCULATIONAHA.111.026591. Epub 2011 Nov 15.

PMID:
22086881
34.

Classification of pediatric pulmonary hypertensive vascular disease: Does it need to be different from the adult classification?

Barst RJ.

Pulm Circ. 2011 Apr-Jun;1(2):134-7. doi: 10.4103/2045-8932.83443. No abstract available.

35.

PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension.

Bokhari S, Raina A, Rosenweig EB, Schulze PC, Bokhari J, Einstein AJ, Barst RJ, Johnson LL.

Circ Cardiovasc Imaging. 2011 Nov;4(6):641-7. doi: 10.1161/CIRCIMAGING.110.963207. Epub 2011 Sep 16.

PMID:
21926260
36.

Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom.

Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JG 6th, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR; Walk-PHASST Investigators.

Circulation. 2011 Sep 27;124(13):1452-60. doi: 10.1161/CIRCULATIONAHA.111.032920. Epub 2011 Sep 6.

37.

Portopulmonary hypertension: a report from the US-based REVEAL Registry.

Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, McGoon MD.

Chest. 2012 Apr;141(4):906-915. doi: 10.1378/chest.11-0160. Epub 2011 Jul 21.

PMID:
21778257
38.

Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management.

Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ.

Chest. 2012 Feb;141(2):363-373. doi: 10.1378/chest.10-3114. Epub 2011 Jul 14.

PMID:
21757572
39.

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.

Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group.

Chest. 2011 Nov;140(5):1274-1283. doi: 10.1378/chest.10-0969. Epub 2011 May 5.

PMID:
21546436
40.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT; walk-PHaSST Investigators and Patients.

Blood. 2011 Jul 28;118(4):855-64. doi: 10.1182/blood-2010-09-306167. Epub 2011 Apr 28.

41.

Pulmonary arterial hypertension: a comparison between children and adults.

Barst RJ, Ertel SI, Beghetti M, Ivy DD.

Eur Respir J. 2011 Mar;37(3):665-77. doi: 10.1183/09031936.00056110. Review.

42.

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.

Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galiè N; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group.

J Heart Lung Transplant. 2011 Jun;30(6):632-43. doi: 10.1016/j.healun.2010.11.009. Epub 2011 Jan 21.

PMID:
21256048
43.

Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.

Ivy DD, Rosenzweig EB, Lemarié JC, Brand M, Rosenberg D, Barst RJ.

Am J Cardiol. 2010 Nov 1;106(9):1332-8. doi: 10.1016/j.amjcard.2010.06.064.

44.

Children deserve the same rights we do: the need for paediatric pulmonary arterial hypertension clinical drug development.

Barst RJ.

Heart. 2010 Sep;96(17):1337-8. doi: 10.1136/hrt.2010.195248. No abstract available.

PMID:
20801850
45.

Pulmonary hypertension and NO in sickle cell.

Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, Kim-Shapiro DB, Machado R, Morris CR, Steinberg MH, Vichinsky EP.

Blood. 2010 Aug 5;116(5):852-4. doi: 10.1182/blood-2010-04-282095. No abstract available.

46.

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD.

Circulation. 2010 Jul 13;122(2):164-72. doi: 10.1161/CIRCULATIONAHA.109.898122. Epub 2010 Jun 28.

PMID:
20585012
47.

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S.

Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7. doi: 10.1164/rccm.201001-0123OC. Epub 2010 Jun 25.

48.

Analysis of the lung allocation score estimation of risk of death in patients with pulmonary arterial hypertension using data from the REVEAL Registry.

Benza RL, Miller DP, Frost A, Barst RJ, Krichman AM, McGoon MD.

Transplantation. 2010 Aug 15;90(3):298-305. doi: 10.1097/TP.0b013e3181e49b83.

PMID:
20559158
49.

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.

Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD.

Chest. 2011 Jan;139(1):128-37. doi: 10.1378/chest.10-0075. Epub 2010 Jun 17. Erratum in: Chest. 2011 Oct;140(4):1106.

PMID:
20558556
50.

Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective.

Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, Zamanian RT, Rubin LJ.

Chest. 2010 Jun;137(6 Suppl):85S-94S. doi: 10.1378/chest.09-2816.

PMID:
20522584

Supplemental Content

Loading ...
Support Center